Company intelligence / Profile preview

Cephagenix

Glostrup, Copenhagen Region, Denmark

Ownership: Private
Development stage: Other

Overview

Cephagenix is a Denmark-based biopharmaceutical joint venture founded in 2020 by Saniona and Professor Jes Olesen (University of Copenhagen) to develop novel migraine treatments based on Saniona’s ion channel CNS platform; its migraine program has achieved successful pre-clinical in vivo validation but has not yet entered clinical trials, and the company recently secured up to €9 million seed funding to advance development.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

SanionaUniversity of Copenhagen / Prof. Jes OlesenAbbVie (via AbbVie Ventures as investor)

Beyond the preview

Go deeper on Cephagenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cephagenix.

Explore the full profile